retatrutide weight loss chart VisualAbstract: reduces body by 17.5% in patients with obesity Retatrutide Results After 40: Realistic
Description
Available at: (Accessed March 15, 2021)
ClinicalTrials.gov: TRIUMPH and TRANSCEND-T2D program trial registry entries
A 2022 systematic review and meta-analysis published in JAMA Internal Medicine found that GLP-1 receptor agonists were associated with increased risks of biliary disease compared to other diabetes medications, with higher risk observed at weight-loss doses and with longer duration of treatment
[DOI] [PMC free article] [PubMed] [Google Scholar] 29.Kanoski S.E., Hayes M.R., Skibicka K.P
